ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES INCLUSION OF FUTURE MEDICAL COSTS IN HEALTH TECHNOLOGY ASSESSMENT GUIDELINES

Published Nov 2, 2016
Vienna, Austria—2 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held an issue panel entitled, Should Health Technology Assessment Guidelines Recommend Inclusion of Future Medical Costs?, at the Society’s 19th Annual European Congress in Vienna, Austria.  The issue panel was moderated by Andrew Briggs, DPhil, MSc, William R, Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK. Panelists for the issue panel included:
  • Alec Morton, PhD, Professor, Management Science, University of Strathclyde, Glasgow, UK
  • Pieter van Baal, PhD, Associate Professor, Institute for Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
  • Ad Antonisse, MSc, Director Economic Affairs (Market Access and Public Affairs), AstraZeneca, Zoetermeer, The Netherlands
This session explored whether health technology assessment (HTA) guidelines should recommend the inclusion of “unrelated future costs” of a medical technology. Recently, Dutch HTA guidelines were changed to recommend inclusion of future, unrelated medical costs. Currently, however, many HTA guidelines exclude future medical costs from an appraisal. For example, the costs of caring for a patient with dementia after preventing death from stroke would not be included in a cost effectiveness analysis of a thrombolysis treatment. The panelists presented the benefits and disadvantages of including future, unrelated costs in HTA guidelines. Alec Morton, PhD provided a summary of theoretical arguments for and against inclusion of future unrelated medical costs. Pieter van Baal, PhD reviewed approaches for how these future costs can be estimated in practice. Ad Antonisse, MSc provided the industry perspective on the issue. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.

ISPOR Announces 2026 Health Economics and Outcomes Research Award Honorees

Apr 21, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced the recipients of its 2026 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards.

ISPOR 2026 Plenaries and Speakers Announced

Apr 8, 2026

ISPOR announced the plenary sessions and speakers for ISPOR 2026, its annual international conference, and the leading global conference for health economics and outcomes research (HEOR). ISPOR 2026 will be held May 17-20 in Philadelphia, PA. The conference convenes nearly 5000 healthcare stakeholders from around the world to discuss topical issues in the field. The content theme for ISPOR 2026 is, “HEOR at the Forefront of Policy, Access, and Value.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×